JP2014520787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520787A5
JP2014520787A5 JP2014517822A JP2014517822A JP2014520787A5 JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122427B2 (ja
JP2014520787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063249 external-priority patent/WO2013004818A1/en
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067.7 2011-07-07
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 true JP2014520787A5 (cg-RX-API-DMAC7.html) 2015-08-13
JP6122427B2 JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (cg-RX-API-DMAC7.html)
EP (1) EP2729130B1 (cg-RX-API-DMAC7.html)
JP (1) JP6122427B2 (cg-RX-API-DMAC7.html)
KR (1) KR102058097B1 (cg-RX-API-DMAC7.html)
CN (1) CN103826616B (cg-RX-API-DMAC7.html)
AU (1) AU2012280198B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000290B1 (cg-RX-API-DMAC7.html)
CA (1) CA2838659C (cg-RX-API-DMAC7.html)
CY (1) CY1121999T1 (cg-RX-API-DMAC7.html)
DK (1) DK2729130T3 (cg-RX-API-DMAC7.html)
EA (1) EA026587B1 (cg-RX-API-DMAC7.html)
ES (1) ES2651212T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171889T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035241T2 (cg-RX-API-DMAC7.html)
IL (1) IL229933A (cg-RX-API-DMAC7.html)
LT (1) LT2729130T (cg-RX-API-DMAC7.html)
MX (1) MX343689B (cg-RX-API-DMAC7.html)
NO (1) NO2729130T3 (cg-RX-API-DMAC7.html)
PL (1) PL2729130T3 (cg-RX-API-DMAC7.html)
PT (1) PT2729130T (cg-RX-API-DMAC7.html)
RS (1) RS56667B1 (cg-RX-API-DMAC7.html)
SI (1) SI2729130T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700574T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013004818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013004818A1 (en) 2011-07-07 2013-01-10 Janssen R&D Ireland Darunavir combination formulations
AU2013225981A1 (en) * 2012-03-01 2014-10-02 Gilead Sciences, Inc. Spray dried formulations
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
BR112019002120A2 (pt) * 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
WO2018029566A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A high drug loaded tablet composition for treating hiv
US20180085387A1 (en) * 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3654951A1 (en) 2017-07-20 2020-05-27 Janssen Sciences Ireland Unlimited Company Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
DE69943266D1 (de) 1998-06-23 2011-04-21 Trustees For The University Of Illinois Board Of Arzneimittel zur behandlung von hiv-infizierten säugetieren
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
US7700645B2 (en) 2002-05-16 2010-04-20 Tibotec Pharmaceuticals Ltd. Pseudopolymorphic forms of a HIV protease inhibitor
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR101372941B1 (ko) 2006-05-30 2014-03-14 얀센 파마슈티카 엔.브이. 히스타민 h3 수용체 조절제로서의 치환된 피리딜 아미드 화합물
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
EA025845B1 (ru) 2006-07-07 2017-02-28 Джилид Сайэнс, Инк. Модуляторы фармакокинетических свойств лекарственных средств
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
CN101790371A (zh) 2007-06-25 2010-07-28 泰博特克药品公司 包含达芦那韦和依曲韦林的组合制剂
AR069539A1 (es) 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
MX2010005488A (es) 2007-11-20 2010-06-01 Janssen Pharmaceutica Nv Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
EP3006032A1 (en) * 2008-05-02 2016-04-13 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
ES2548886T3 (es) * 2009-02-06 2015-10-21 Gilead Sciences, Inc. Comprimidos bicapa que comprenden elvitegravir, cobicistat, emtricitabina y tenofovir
EP2477992B1 (en) * 2009-09-17 2016-12-14 Mylan Laboratories Limited Processes for the preparation of darunavir and the amorphous form thereof
WO2011141921A1 (en) 2010-05-10 2011-11-17 Hetero Research Foundation Darunavir compositions
WO2013004818A1 (en) 2011-07-07 2013-01-10 Janssen R&D Ireland Darunavir combination formulations
ES2598823T3 (es) 2011-07-07 2017-01-30 Janssen R&D Ireland Formulaciones de darunavir
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
AU2015373104B2 (en) 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2011093937A5 (cg-RX-API-DMAC7.html)
JP2013539946A5 (cg-RX-API-DMAC7.html)
JP2013531034A5 (cg-RX-API-DMAC7.html)
JP2013531018A5 (cg-RX-API-DMAC7.html)
JP2014503786A5 (cg-RX-API-DMAC7.html)
JP2012023335A5 (cg-RX-API-DMAC7.html)
JP2014026276A5 (cg-RX-API-DMAC7.html)
JP2014026274A5 (cg-RX-API-DMAC7.html)
JP2014026275A5 (cg-RX-API-DMAC7.html)
JP2014505137A5 (cg-RX-API-DMAC7.html)
JP2015500269A5 (cg-RX-API-DMAC7.html)
JP2012204203A5 (cg-RX-API-DMAC7.html)
JP2013064178A5 (cg-RX-API-DMAC7.html)
JP2014189812A5 (cg-RX-API-DMAC7.html)
JP2014520787A5 (cg-RX-API-DMAC7.html)
JP2015107586A5 (cg-RX-API-DMAC7.html)
JP2012193264A5 (cg-RX-API-DMAC7.html)
JP2012190699A5 (cg-RX-API-DMAC7.html)
JP2014531903A5 (cg-RX-API-DMAC7.html)
JP2011233516A5 (cg-RX-API-DMAC7.html)
JP2014534151A5 (cg-RX-API-DMAC7.html)
JP2014520786A5 (cg-RX-API-DMAC7.html)
JP2014005521A5 (cg-RX-API-DMAC7.html)
JP2013016377A5 (cg-RX-API-DMAC7.html)
JP2015127764A5 (cg-RX-API-DMAC7.html)